Xiamen Innovax Biotech Co., Ltd.

About us

Xiamen Innovax Biotech Co., Ltd. (“Innovax”), with a registered capital of RMB 1.2 billion, was founded in Mar, 2005. It is the key vaccine arm of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., and the only private-owned hightech enterprise engaged in vaccine research, development and production in Fujian Province.

Having been dedicated to the vaccine industry for nearly 20 years, Innovax is committed to providing high-quality, affordable and innovative vaccines for human being. With a sustainable industry-academia-research model, Innovax closely collaborated with the “National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)” and established the world’s first E.coli platform for recombinant virus-like particle vaccines, and successfully launched the world’s first recombinant hepatitis E vaccine (Hecolin^®) and the first HPV vaccine (Cecolin^®) in the Chinese market. (the 4th HPV vaccine in the world).

Main Product

Hecolin® Cecolin® Cecolin®9 Recombinant Respiratory Syncytial Virus (RSV) Vaccine Third-Generation HPV Vaccine 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Hecolin®

As the world's only HEV vaccine, Hecolin® hepatitis E vaccines vaccine was launched in October 2012. Being the first viral vaccine developed with E. coli expression system, Hecolin® HEV vaccine completely reversed the perception the global academic community holds that “the prokaryotic system cannot be used for the development of virus vaccines”.

Cecolin®

As China’s first HPV vaccine, Cecolin® HPV 16&18 vaccine was approved by the National Medical Products Administration on December 30, 2019, which made China the third country in the world that can achieve independent supply of HPV vaccines, following only the United States and the United Kingdom.

Cecolin®9

In 2025, China's National Medical Products Administration (NMPA) approved Cecolin®9, the first HPV 9-valent vaccine in developing counrty originated from China. As the second HPV 9-valent vaccine available worldwide, it breaks the long-standing global technological monopoly held by imported high-valency HPV vaccines. This milestone marks China as the second nation (after the United States) with complete, independent capabilities to sustainable supply of a high-valency HPV vaccine.

Recombinant Respiratory Syncytial Virus (RSV) Vaccine

A novel vaccine with proprietary intellectual property, developed using a CHO cell expression system and a novel adjuvant. Preclinical studies have demonstrated promising immunogenicity and safety profiles, and the vaccine is currently in the preclinical research phase.

Third-Generation HPV Vaccine

As a leading manufacturer of the first HPV vaccine brand in developing countries, Innovax continues to advance innovation in cervical cancer prevention. Leveraging structural vaccinology, Innovax has independently designed a multi-valent chimeric epitope HPV vaccine with broad-spectrum protection.

20-Valent Pneumococcal Polysaccharide Conjugate Vaccine

In February 2021, Innovax licensed the 20-valent pneumococcal polysaccharide-protein conjugate vaccine technology from Jiangsu Kunli Biopharmaceutical Co., Ltd.. Clinical trial approval was obtained in September 2021, and the Phase 1 clinical trial is currently progressing as planned.

News

least news

Links: